Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study

Incretins reduce glycemic variability (GV) in patients with type 2 diabetes, but it is unknown whether switching from a combination of basal insulin and a DPP-4 inhibitor to insulin degludec/liraglutide (IDegLira) improves GV. We performed an exploratory prospective observational study to compare th...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Yuki Oe, Hiroshi Nomoto, Akinobu Nakamura, Saki Kuwabara, Yuka Takahashi, Ayano Yasui, Rimi Izumihara, Aika Miya, Hiraku Kameda, Kyu Yong Cho, Tatsuya Atsumi, Hideaki Miyoshi
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2022-01-01
coleção:	Journal of Diabetes Research
Acesso em linha:	http://dx.doi.org/10.1155/2022/5603864
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!